A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer

Mol Cancer. 2023 Jan 20;22(1):13. doi: 10.1186/s12943-022-01699-2.
No abstract available

Keywords: Adjuvant chemotherapy; Colorectal cancer; FOLFOX; MicroRNA; Predictive biomarker.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chemotherapy, Adjuvant
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / genetics
  • Colorectal Neoplasms* / pathology
  • Combined Modality Therapy
  • Fluorouracil / therapeutic use
  • Humans
  • MicroRNAs* / genetics
  • Neoplasm Staging
  • Prognosis

Substances

  • MicroRNAs
  • Fluorouracil